tbuckley/cabot-search huggingface dataset:
A New Familial Cancer Syndrome? A Spectrum of Malignant and Benign Tumors Including Retinoblastoma, Carcinoma of the Bladder and Other Genitourinary Tumors, Thyroid Adenoma, and a Probable Case of Multifocal Osteosarcoma2
Authors: Helen Chan, Charles B. Pratt
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article A New Familial Cancer Syndrome? A Spectrum of Malignant and Benign Tumors Including Retinoblastoma, Carcinoma of the Bladder and Other Genitourinary Tumors, Thyroid Adenoma, and a Probable Case of Multifocal Osteosarcoma Get access Helen Chan, Helen Chan Search for other works by this author on: Oxford Academic PubMed Google Scholar Charles B. Pratt Charles B. Pratt 3 3St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, Tenn. 38101. Address reprint requests to Dr. Pratt. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 2, February 1977, Pages 205–207, https://doi.org/10.1093/jnci/58.2.205 Published: 01 February 1977 Article history Received: 19 April 1976 Accepted: 28 June 1976 Published: 01 February 1977
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection
Authors: Hashem B. El‐Serag, Fasiha Kanwal, Peter Richardson, Jennifer Kramer
Journal: Hepatology (2016)

The long-term prognosis in terms of risk or predictors of developing hepatocellular carcinoma (HCC) among patients with sustained virological response (SVR) remains unclear. We conducted a retrospective cohort study using data from the Veterans Affairs VA hepatitis C virus (HCV) Clinical Case Registry in patients with positive HCV RNA between October 1999 and August 2009 and follow-up through December 2010. HCV treatment (interferon with or without ribavirin) and SVR (RNA test negative at least 12 weeks after the end of treatment) were determined. We used Cox's proportional hazards models to calculate hazard ratios (HRs) for potential predictors (demographic, virological, and clinical) associated with HCC development post-SVR. We identified 33,005 HCV-infected individuals who received treatment, of whom 10,817 achieved SVR. Among these patients, 100 developed new HCC during a total follow-up of 30,562 person-years for an overall incidence rate of 0.33% per year. Annual risk of HCC remained considerably high among patients with cirrhosis (1.39%) and those cured after age 64 (0.95%). Patients with diabetes (adjusted HR = 1.88; 1.21-2.91) or genotype 3 infection (adjusted HR = 1.62; 0.96-2.734) were significantly more likely to develop HCC.Risk of HCC after HCV cure, though considerably reduced, remains relatively high at 0.33% per year. Older age and/or presence of cirrhosis at the time of SVR are associated with a high enough risk to warrant surveillance. Diabetes is also a risk factor for post-SVR HCC. (Hepatology 2016;64:130-137).
Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT)
Authors: Luigi Gugliotta, Alessandra Iurlo, Alessia Tieghi, Gabriele Gugliotta, Anna Candoni, Elisa Rumi, Elisabetta Antonioli, Alessandra Ricco, Monica Lunghi, Rosario Potito Scalzulli, Anna Rita Scortechini, Katia Codeluppi, Bruno Martino, Alfredo Dragani, Andrea Patriarca, Vincenzo Martinelli, Giorgia Battipaglia, Maria Luigia Randi, Elisabetta Cosi, Anna Marina Liberati, Viviana Appolloni, Nilla Maschio, Lucia Mastrullo, Maria Rosaria Villa, Maria Rosaria Esposito, Nicola Cantore, Fausto Palmieri, Maria Langella, Flavia Rivellini, Maria Gabriella Mazzucconi, Cristina Santoro, Ercole De Biasi, Angela Rago, Nicola Polverelli, Pierangelo Spedini, Emma Cacciola, Rossella R Cacciola, Ivana Pierri, Laura Mitsheunig, Marzia Salvucci, Ferdinando Porretto, Andrea Piccin, Umberto Santoro, Gianluca Gaidano, Giuseppe Cimino, Francesco Lanza, Agostino Cortelezzi, Giuseppe Tagariello, Serena Rupoli, Giorgina Specchia, Francesco Passamonti, Alessandro M. Vannucchi, Fabrizio Pane, Nicola Vianelli, Rossella Miglio, Paola Monari
Journal: Blood (2013)
CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma
Authors: Linfeng Chen, Yansheng Hao, Jing Ouyang, Bjoern Chapuy, Donna S. Neuberg, Thomas M Habermann, Przemyslaw Juszczynski, Scott J Rodig, Stefano Monti, Margaret A Shipp
Journal: Blood (2013)
Abstract 16121: Recombinant Human Placental Growth Factor 2 is a Safe and Effective Therapy for Ischemic Cardiomyopathy in Atherosclerotic Mice
Authors: Ming Wu, Melissa Swinnen, Ellen Caluwe, Hilde Gillijns, Nina Vanden Driessche, Peter Pokreisz, Stefan Janssens
Journal: Circulation (2014)

Aim: Angiogenic growth factor therapy carries a risk of stimulating atherosclerotic plaque growth. We evaluated whether systemic infusion of recombinant human placental growth factor (rhPlGF) 2 improves myocardial neovascularization, left ventricular (LV) function and adverse remodeling in a murine model of advanced atherosclerosis and chronic myocardial infarction (MI) without increasing atherosclerotic plaque size and plaque vulnerability. Methods: ApoE -/- mice were fed a high cholesterol diet and MI was induced 4 weeks (w) later using 60 min LAD occlusion followed by reperfusion. After 8 w, we assessed LV function using echocardiography and randomized mice to receive rhPlGF2 (450μg/kg/day, n=20) or PBS (n=20) via osmotic minipumps for 28 days. Echocardiography and histological analyses were performed at 12 and 20 w. Results: Infusion of rhPlGF2 increased PlGF plasma levels for 3 w up to ~1600-fold without adverse side effects, or changes in total cholesterol and high sensitive CRP levels. In rhPlGF2-treated mice, capillary and arteriolar density was significantly higher in ischemic myocardium (2813±212 capillaries/mm 2 at 12 w vs 2144±478 in PBS, P &lt;0.05; 125±18 arterioles/mm 2 at 20 w vs 77±13 in PBS, P =0.001). RhPlGF2 significantly improved ejection fraction (EF), reduced LV end-systolic and end-diastolic volume indices at 12 w and prevented further LV dilation and EF deterioration at 20 w (Figure). RhPlGF2 did not increase plaque area in the aortic arch, or the degree of fibrosis, calcification, capillary or arteriolar density and MAC3-positive cell areas in plaques at 12 and 20 w. Conclusion: Systemic rhPlGF2 infusion significantly improves neovascularization and contractile function, and prevents LV adverse remodeling in chronic ischemic cardiomyopathy without increasing atherosclerotic plaque burden or plaque vulnerability. RhPlGF2 may represent a promising and safe therapeutic strategy in chronic ischemic cardiomyopathy.
Heterologous Transplantation, Chromosome Analyses, and DNA Measurements of the Human Carcinoma Tissue Culture Line, H.Ep. #22
Authors: Gisela Haemmerli, Audrey Fjelde, Alfred Zweidler, Peter Sträuli
Journal: JNCI Journal of the National Cancer Institute (1966)

The human epidermoid carcinoma No.2 (H.Ep. #2), which had been kept continuously in tissue culture since 1953, was transplanted into adult, conditioned golden hamsters. Morphologically, the transplanted tumors resembled closely the original tissue from the patient. Chromosome analyses were performed on two series of H.Ep. #2 cells, both originating from Fjelde stock cultures. The First series comprised the first stock culture from Fjelde (TCF), the corresponding First hamster tumor line (H.Ep. #2/H1), and material from the latter brought back into tissue culture (H.Ep. #2/H1-TC). The second series included the second tissue culture material (H.Ep. #2/TC2) and the ensuing second hamster tumor line (H.Ep. #2/H2). Chromosome numbers of cells of the first series varied between 69 and 80, with a large peak at 74–75 and a smaller peak at 77. Four marker chromosomes were present. In the second series, a large peak was found at 69–70 and a smaller peak at 74–75. Besides the 4 markers from the First series, the cells within these peaks possessed 2 new markers, each of them characteristic for one of the peaks. The different peaks in the frequency distribution of the chromosome numbers were interpreted as representing 2 stemlines. In the first series this assumption was based on chromosome numbers only, whereas in the second series it was corroborated by the presence of the individual marker chromosomes. DNA was measured on Feulgenstained nuclei of H.Ep. #2 cells grown in vivo and in vitro. Both tumor cell lines showed their DNA values to be aggregated in two peaks: one around 3.5c and the other around 7c. Thus a correlation was established between the amount of DNA and the hypertriploid chromosome number of H.Ep. #2 cells.
Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs)
Authors: Bruno Paiva, Luis A Corchete, Norma Gutierrez, María-Belén Vidriales, Irene Aires-Mejia, Maria Luz Sanchez, Paloma Barcena, Teresa Paíno, María Asunción Echeveste, Miguel Hernandez, Ramon Garcia-Sanz, Enrique M. Ocio, Albert Oriol, Mercedes Gironella, Luis Palomera, Felipe de Arriba, Yolanda Gonzalez, Juan-Jose Lahuerta, Joan Blade, Alberto Orfao, Maria-Victoria Mateos, Jesus F San Miguel
Journal: Blood (2013)
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Vatche Tchekmedyian, Eric J. Sherman, Lara Dunn, Crystal Tran, Shrujal Baxi, Nora Katabi, Cristina R. Antonescu, Irina Ostrovnaya, Sofia S. Haque, David G. Pfister, Alan L. Ho
Journal: Journal of Clinical Oncology (2019)

PURPOSE Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin for which effective therapies are lacking. We conducted a phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib in patients with R/M ACC. PATIENTS AND METHODS This study was conducted with a two-stage minimax design. Patients with histologically confirmed R/M ACC of any primary site with radiographic and/or symptomatic progression were eligible. Any prior therapy was allowed except previous lenvatinib. Patients received lenvatinib 24 mg orally per day. The primary end point was overall response rate. Secondary end points were progression-free survival and safety. An exploratory analysis of how MYB expression and genomic alterations relate to outcomes was conducted. RESULTS Thirty-three patients were enrolled; 32 were evaluable for the primary end point. Five patients (15.6%) had a confirmed partial response, 24 patients (75%) had stable disease, two patients (6.3%) discontinued treatment as a result of toxicity before the first scan, and one patient (3.1%) had progression of disease as best response. Median progression-free survival time was 17.5 months (95% CI, 7.2 months to not reached), although only eight progression events were observed. Patients otherwise were removed for toxicity (n = 5), as a result of withdrawal of consent (n = 9), or at the treating physician’s discretion (n = 6). Twenty-three patients required at least one dose modification, and 18 of 32 patients discontinued lenvatinib for drug-related issues. The most common grade 3 or 4 adverse events were hypertension (n = 9; 28.1%) and oral pain (n = 3; 9.4%). Three grade 4 adverse events were observed (myocardial infarction, n = 1; posterior reversible encephalopathy syndrome, n = 1; and intracranial hemorrhage, n = 1). CONCLUSION This trial met the prespecified overall response rate primary end point, demonstrating antitumor activity with lenvatinib in R/M ACC patients. Toxicity was comparable to previous studies, requiring monitoring and management.
Pediatric Hodgkin's disease in India.
Authors: K Dinshaw, S Pande, S Advani, G Ramakrishnan, C Nair, G Talvalkar, D N Rao, P Notani, R Rao, P Desai
Journal: Journal of Clinical Oncology (1985)

Twenty-one percent of all Hodgkin's disease in India was seen in the pediatric age groups at the Tata Memorial Hospital (Bombay, India). From 1975 to 1982, 151 cases of children were reviewed. The youngest presentation was at 3 years in three patients, with a marked male: female ratio of 5.5:1. Twenty-six patients were previously treated before referral while the remaining 125 cases were investigated and treated according to the prevalent protocols in 1975 to 1978 and 1979 to 1982. Clinical staging revealed 54% of patients in stages I and II with symptoms in 20%, and 46% of patients in stages III and IV with symptoms in 67%. Staging laparotomy was performed in 27 patients, with a total changes of staging in 17 children (63%). The mixed cell types (46%) and lymphocytic predominant types (31%) were the most common histologic presentations. Nine percent nodular sclerosis and 9% lymphocytic-depleted varieties were also observed. Five percent of all cases were not classifiable. Minimum adequate treatment was completed in 87 cases. Comparisons were made between the treatments administered to 40 patients during the initial period 1975 to 1978 when individualized treatment was administered, and the later 47 patients during the 1979 to 1982 period, when chemotherapy was the mainstay of treatment with involved field radiation.
Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells
Authors: Kimberly S. Lucenay, Iman Doostan, Cansu Karakas, Tuyen Bui, Zhiyong Ding, Gordon B. Mills, Kelly K. Hunt, Khandan Keyomarsi
Journal: Cancer Research (2016)

Cyclin E is altered in nearly a third of invasive breast cancers where it is a powerful independent predictor of survival in women with stage I-III disease. Full-length cyclin E is posttranslationally cleaved into low molecular weight (LMW-E) isoforms, which are tumor-specific and accumulate in the cytoplasm because they lack a nuclear localization sequence. We hypothesized that aberrant localization of cytosolic LMW-E isoforms alters target binding and activation ultimately contributing to LMW-E-induced tumorigenicity. To address this hypothesis, we used a retrovirus-based protein complementation assay to find LMW-E binding proteins in breast cancer, identifying ATP-citrate lyase (ACLY), an enzyme in the de novo lipogenesis pathway, as a novel LMW-E-interacting protein in the cytoplasm. LMW-E upregulated ACLY enzymatic activity, subsequently increasing lipid droplet formation, thereby providing cells with essential building blocks to support growth. ACLY was also required for LMW-E-mediated transformation, migration, and invasion of breast cancer cells in vitro along with tumor growth in vivo In clinical specimens of breast cancer, the absence of LMW-E and low expression of adipophilin (PLIN2), a marker of lipid droplet formation, associated with favorable prognosis, whereas overexpression of both proteins correlated with a markedly worse prognosis. Taken together, our findings establish a novel relationship between LMW-E isoforms of cyclin E and aberrant lipid metabolism pathways in breast cancer tumorigenesis, warranting further investigation in additional malignancies exhibiting their expression. Cancer Res; 76(8); 2406-18. ©2016 AACR.
Erectile dysfunction in patients with liver disease related to chronic hepatitis B
Authors: Min Kim, Seul Young Kim, Woo Sun Rou, Se Woong Hwang, Byung Seok Lee
Journal: Clinical and Molecular Hepatology (2015)

Background/Aims Despite sexual function making an important contribution to the quality of life, data on erectile function are relatively scant in patients with chronic liver disease. We evaluated the prevalence of and risk factors for erectile dysfunction (ED) in patients with liver disease related to hepatitis B, especially among those with chronic hepatitis B (CHB) or early-stage cirrhosis. Methods In total, 69 patients (35 with CHB and 34 with hepatitis-B-related liver cirrhosis [HBV-LC]) aged 40-59 years were analyzed. Child-Pugh classes of A and B were present in 30 (88.2%) and 4 (11.8%) of the patients with HBV-LC, respectively. The erectile function of the patients was evaluated using the Korean version of IIEF-5. Results The prevalence of any ED was 24.6% for all patients, and 8.6% and 41.2% for those with CHB and HBV-LC, respectively (P=0.002). While there was only one (2.9%) CHB patient for each stage of ED, mild, moderate, and severe ED stages were seen in three (8.8%), one (2.9%), and ten (29.4%) of the HBV-LC patients, respectively. Multiple regression analysis identified the type of liver disease (P=0.010), hypertension (P=0.022), score on the Beck Depression Inventory (P =0.044), and the serum albumin level (P=0.014) as significant independent factors for the presence of ED. Conclusions The prevalence of ED was significantly higher in patients with early-stage HBV-LC than in those with CHB. Therefore, screening male patients with early viral cirrhosis for ED and providing appropriate support are needed, especially when the cirrhosis is accompanied by hypertension, depression, or a depressed level of serum albumin. Keywords: Liver disease; Chronic hepatitis B; Liver cirrhosis; Erectile dysfunction
Deuterium Isotope Effect in the Microsomal Metabolism of Dimethylnitrosamine2
Authors: Doron Dagani, Michael C. Archer
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Deuterium Isotope Effect in the Microsomal Metabolism of Dimethylnitrosamine Get access Doron Dagani, Doron Dagani Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael C. Archer Michael C. Archer Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 4, October 1976, Pages 955–957, https://doi.org/10.1093/jnci/57.4.955 Published: 01 October 1976 Article history Received: 22 January 1975 Accepted: 29 March 1976 Published: 01 October 1976
Abstract 13114: Predictive Value of the Has-Bled Score in Patients with Atrial Fibrillation and Chronic Kidney Disease Using Vitamin K-Antagonists
Authors: Judith Kooiman, Cornelis A van Beers, Bas Spaans, Jonna R Bank, Suzanne C Cannegieter, G. Y Lip, Felix J van der Meer, Ton J Rabelink, Menno V Huisman
Journal: Circulation (2012)

Aim The HAS-BLED score enables a risk estimate of major bleeding in patients with atrial fibrillation (AF) on vitamin K-antagonists (VKA) treatment, but has never been validated in patients with ch...
A stem-loop "kissing" model for the initiation of recombination and the origin of introns.
Authors: D R Forsdyke
Journal: Molecular Biology and Evolution (1995)

Mutations which improve the efficiency of recombination should affect either the proteins which mediate recombination or their substrate, DNA itself. The former mutations would be localized to a few sites. The latter would be dispersed. Studies of hybridization between RNA molecules have suggested that recombination may be initiated by a homology search involving the "kissing" of the tips of stem loops. This predicts that, in the absence of other constraints, mutations which assist the formation of stem loops would be favored. From comparisons of the folding of normal and shuffled DNA sequences, I present evidence for an evolutionary selection pressure to distribute stem loops generally throughout genomes. I propose that this early pressure came into conflict with later local pressures to impose information concerning specific function. The conflict was accommodated by permitting sections of DNA concerned with a specific function to evolve in dispersed segments. Traces of the conflict seem to be present in some modern intron-containing genes. Thus, introns may have allowed the interspersing of selectively advantageous stem loops in coding regions of DNA.
Interaction of Oxygen and Oxy-radicals With Carotenoids&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: Norman I. Krinsky, Susan M. Deneke
Journal: JNCI Journal of the National Cancer Institute (1982)

Dye-sensitized photo-oxidations of liposomes are inhibited by the presence of carotenoids in the membrane. Some carotenoid bleaching occurs during the reaction. It was shown that carotenoids are capable of inhibiting free-radical-induced lipid peroxidation in liposomes as well as singlet oxygen-induced lipid peroxidation. There is little direct effect of lipid peroxides on carotenoid bleaching during the photo-oxidative reactions. The carotenoid bleaching observed during the dye-photosensitized oxidations of the liposomes appears to be due to interactions between the carotenoid pigments and either radical intermediates from type I reactions or direct chemical reaction with singlet oxygen in a type II reaction. It was concluded that carotenoid pigments function as protective agents by quenching triplet sensitizers, singlet oxygen, and radical intermediates.
Abstract 18846: Impact of Bleeding on Length of Stay and Total Cost in Atrial Fibrillation Patients
Authors: Alpesh N Amin, Bruce D Bowdy, Bernadette H Johnson, Yonghua Jing, Scott B Robinson, Danny Wiederkehr
Journal: Circulation (2012)

Objectives: To determine the impact of hospital acquired bleeding assessed in patients admitted for atrial fibrillation (AF) on length of stay (LOS) and total hospitalization cost. Methods: The Premier research database was queried to identify adult inpatients discharged between 2008 and 2011 who had a primary diagnosis code of AF and in whom bleeding was not present on admission. Bleeding was identified using ICD-9 diagnosis codes, charge codes for fresh frozen plasma or blood, or charge codes for transfusion of blood or blood components. Patients considered extreme outliers for LOS (greater than 1 standard deviation [SD] above the mean) were excluded from the study. Descriptive statistics including the outcomes of LOS and total hospitalization cost were calculated. In the univariate comparison of patients with and without bleeding, t-tests for continuous variables and chi-squared tests for categorical variables were used (alpha = 0.05). Gamma regression adjusting for demographics, comorbidities and antiplatelet/anticoagulant use were used to produce adjusted estimates for mean LOS and total hospitalization cost among patients with and without bleeding. Results: There were 143,415 patients, average age of 69.4 (SD 14.5) that met the study criteria. Across the entire population, mean LOS was 3.5 (SD 3.1) days, and mean total cost was $7,498 (SD 8,557). Overall, 3,058 (2.1%) patients had a bleed during their hospitalization. After adjustment, the mean estimated LOS was 6.68 (95% CI 6.52-6.84) days in the bleed group and 3.28 (95% CI 3.27-2.29) days in the no bleed group. The adjusted mean estimated total hospitalization cost was greater in the bleed group $16,621 (95% CI 16,178-17,074) vs. $6,996 (95% CI 6,969-7,023) in the no bleed group. Conclusions: Occurrence of hospital acquired bleeding in patients with AF is associated with a significant increase in the LOS and total hospitalization cost. In this study, adjustment for demographic and comorbidity differences as well as the use of antiplatelets and anticoagulants did not change the magnitude or direction of these associations, though there may be residual confounding. In this cohort, the effect of bleeding accounted for approximately $30 million dollars in cost and 10,397 hospitalization days.